Trial · NCT04130919
Results by group45
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 45
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants Who Achieved Clinical Remission Per Modified Mayo Clinic Score (MCS) at Week 10 | Tilpisertib 300 mg (Blinded Treatment Phase) | 0 | percentage of participants | ||
| Percentage of Participants Who Achieved Clinical Remission Per Modified Mayo Clinic Score (MCS) at Week 10 | Tilpisertib 100 mg (Blinded Treatment Phase) | 0 | percentage of participants | ||
| Percentage of Participants Who Achieved Clinical Remission Per Modified Mayo Clinic Score (MCS) at Week 10 | Placebo (Blinded Treatment Phase) | 0 | percentage of participants | ||
| Percentage of Participants Who Achieved Endoscopic Response at Week 10 | Tilpisertib 300 mg (Blinded Treatment Phase) | 14.3 | percentage of participants | ||
| Percentage of Participants Who Achieved Endoscopic Response at Week 10 | Tilpisertib 100 mg (Blinded Treatment Phase) | 16.7 | percentage of participants | ||
| Percentage of Participants Who Achieved Endoscopic Response at Week 10 | Placebo (Blinded Treatment Phase) | 0 | percentage of participants | ||
| Percentage of Participants Who Achieved MCS Response at Week 10 | Tilpisertib 300 mg (Blinded Treatment Phase) | 28.6 | percentage of participants | ||
| Percentage of Participants Who Achieved MCS Response at Week 10 | Tilpisertib 100 mg (Blinded Treatment Phase) | 16.7 | percentage of participants | ||
| Percentage of Participants Who Achieved MCS Response at Week 10 | Placebo (Blinded Treatment Phase) | 16.7 | percentage of participants | ||
| Percentage of Participants Who Achieved MCS Remission at Week 10 | Tilpisertib 300 mg (Blinded Treatment Phase) | 0 | percentage of participants | ||
| Percentage of Participants Who Achieved MCS Remission at Week 10 | Tilpisertib 100 mg (Blinded Treatment Phase) | 0 | percentage of participants | ||
| Percentage of Participants Who Achieved MCS Remission at Week 10 | Placebo (Blinded Treatment Phase) | 0 | percentage of participants | ||
| Percentage of Participants Who Achieved Histologic Remission Based Upon the Geboes Scale at Week 10 | Tilpisertib 300 mg (Blinded Treatment Phase) | 16.7 | percentage of participants | ||
| Percentage of Participants Who Achieved Histologic Remission Based Upon the Geboes Scale at Week 10 | Tilpisertib 100 mg (Blinded Treatment Phase) | 16.7 | percentage of participants | ||
| Percentage of Participants Who Achieved Histologic Remission Based Upon the Geboes Scale at Week 10 | Placebo (Blinded Treatment Phase) | 25.0 | percentage of participants | ||
| Percentage of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs) | Tilpisertib 300 mg (Blinded Treatment Phase) | 57.1 | percentage of participants | ||
| Percentage of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs) | Tilpisertib 100 mg (Blinded Treatment Phase) | 50.0 | percentage of participants | ||
| Percentage of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs) | Placebo (Blinded Treatment Phase) | 50.0 | percentage of participants | ||
| Percentage of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs) | Tilpisertib 300 mg From Tilpisertib 300 mg (Open-label Treatment Phase) | 50.0 | percentage of participants | ||
| Percentage of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs) | Tilpisertib 300 mg From Tilpisertib 100 mg (Open-label Treatment Phase) | 66.7 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04130919/results